Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918008 · ClinicalTrials.gov registry record
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 12
- Enrollment target
NCT00918008: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00918008 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00918008 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances of recurrence of cancer after their surgery. Some patients who are diagnosed with bladder cancer and have their had bladder removed, will have a recurrence of cancer sometime after their surgery. This recurrence is usually caused by tumor cells that originated from the bladder tumor and traveled to other parts of the body, which is called metastatic cancer. Some patients are more likely than others to have metastatic disease. This test may help in identifying these patients who might develop metastases from having these specific genes.
Interventions
- GENETIC Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918008
The ClinicalTrials.gov registry entry for NCT00918008 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT00918008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00918008 about?
NCT00918008 is a clinical study titled "A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer". The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances of recurrence of cancer after their surgery. Some patients who are dia...
What is the current status of trial NCT00918008?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2009-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00918008?
The interventions under investigation include: Blood draw (GENETIC).
Who is sponsoring clinical trial NCT00918008?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.